|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2010-8-5
|
|
pubmed:databankReference |
|
|
pubmed:abstractText |
The oxazolidinone PNU-100480 is superior to linezolid against experimental murine tuberculosis. Two metabolites contribute to but do not fully account for its superiority. This study examined the safety, tolerability, pharmacokinetics, and mycobactericidal activity of single ascending doses of PNU-100480.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
1537-6613
|
|
pubmed:author |
pubmed-author:CampbellSheldonS,
pubmed-author:DimitrovaDessislavaD,
pubmed-author:FriedlandGeraldG,
pubmed-author:JakubiecWesley MWM,
pubmed-author:KumarVikasV,
pubmed-author:LadutkoLynnL,
pubmed-author:LiXiaoxiX,
pubmed-author:MillerPaul FPF,
pubmed-author:Mitton-FryMarkM,
pubmed-author:PaigeDarcyD,
pubmed-author:SilviaAnnette MAM,
pubmed-author:WallisRobert SRS
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
1
|
|
pubmed:volume |
202
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
745-51
|
|
pubmed:dateRevised |
2010-12-1
|
|
pubmed:meshHeading |
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Pharmacokinetics and whole-blood bactericidal activity against Mycobacterium tuberculosis of single doses of PNU-100480 in healthy volunteers.
|
|
pubmed:affiliation |
Pfizer, 50 Pequot Avenue, New London, CT 06320, USA. robert.wallis@pfizer.com
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase I
|
